2021 Inventory of Prostate Cancer Research Progress in China

On January 8, the "2022 Beijing Urological Cancer Youth Forum" was successfully held by the Youth Committee of the Urology and Male Genital Oncology Committee of the Beijing Anti-Cancer Association and the Beijing Medical Award Foundation
.

During the meeting, Professor Li Yonghong of Sun Yat-Sen University Cancer Center shared the articles published by Chinese researchers in prostate cancer-related fields in 2021 and recommended relevant research progress
.

Number of Published Articles In 2020, Chinese scholars published a total of 1,359 articles, and the number of articles published in 2021 will increase, with a total of 1,457 articles published
.

In 2021, the top 20 institutions for the number of articles published in the field of prostate cancer in China are Shanghai Jiaotong University, Sun Yat-sen University, Zhejiang University, Sichuan University, Peking University, Peking Union Medical College, Huazhong University of Science and Technology, Fudan University, Nanjing Medical University, Zhengzhou University, Suzhou University, Southern Medical University, Central South University, Tianjin Medical University, Shandong University, Xi'an Jiaotong University, Tongji University, Anhui Medical University, China Medical University, Chinese University of Hong Kong
.

Researchers who have published more than 4 articles in the field of prostate cancer In 2021, there are 14 researchers who have published more than 4 articles in the field of prostate cancer in China: Yan Weigang (Peking Union Medical College), Wu Tao (North Sichuan Medical College), Wang Xiaoying (Beijing) University), Wang Haifeng (Tongji University), Wu Zhihui (Chinese University of Hong Kong), Li Hongjun (Peking Union Medical College), Zhong Weide (South China University of Technology), Shang Zhiqun (Tianjin Medical University), Li Gonghui (Zhejiang University), Chen Ming (Southeast China University) University), Zeng Hao (Sichuan University), Liang Chaochao (Anhui Medical University), Hou Jianquan (Soochow University), Xue Wei (Shanghai Jiaotong University)
.

Professor Li pointed out that there may be omissions in the article retrieval.
For example, the team of Professor Ye Dingwei of Fudan University has also published many studies.
If there are other omissions, please forgive me
.

The top 20 journals published by Chinese scholars in the field of prostate cancer are shown in the figure
.

Chinese researchers have also published relevant articles in internationally renowned journals, including 1 article on EUROPEAN UROLOGY (IF: 20.
096), 2 articles in BRITISH JOURNAL OF CANCER (IF: 7.
64), 3 articles in WORLD JOURNAL OF UROLOGY (IF: 4.
226), and 3 articles in CANCER RESEARCH (IF: 12.
701) 4 articles, JOURNAL OF UROLOGY (IF: 7.
45) 4 articles, INTERNATIONAL JOURNAL OF CANCER (IF: 7.
396) 5 articles
.

Renji Hospital Xue Wei Dong Baijun (chemotherapy).
3.
Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
JU.
Renji Hospital Xue Wei Dong Baijun (sequencing).
4.
Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
JU.
Renji Hospital Xue Wei Dong Baijun (sequencing).
5.
Can Ga-68-PSMA-11 Positron Emission Tomography/Computerized Tomography Predict Pathological Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy ? A Pilot Study.
JU.
.
Guo Hongqian, Qiu Xuefeng, Nanjing University Drum Tower Hospital, Wang Feng, Nanjing First Hospital (image).
6.
Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.
IJC.
West China Hospital Li Zheng and Bi Feng ( New drugs for endocrine therapy).
7.
Association of body composition with risk of overall and site-specific cancers: A population-based prospective cohort study.
IJC.
The Seventh Affiliated Hospital of Sun Yat-Sen University, Zhang Changhua, Jinqiu Yuan, He Yulong (metabolism).
8.

.

Professor Han Bo's research revealed a potential therapeutic target, KIF-15 may be used as a therapeutic target for prostate cancer after enzalutamide treatment resistance
.

Phase I study of the new endocrine drug HC-1119, which is characterized by low concentration in the brain and higher safety
.

The above three studies are all research progresses related to endocrine therapy, and they are also one of the key areas of focus for prostate cancer
.

Key recommendation 2: Prostate cancer progression and metastasis mechanism published in CANCER RESEARCH These two studies respectively suggest that the MAP3K7-IKK inflammatory signaling pathway is associated with prostate cancer invasion; SPOP E3 mutant ligase promotes the degradation of 17βHSD4 protein to drive androgen production and prostate cancer progress
.

Associated mutations may also serve as therapeutic targets for the androgen receptor (AR)
.

The three studies shown in the figure are also similar to the previous two studies, which also revealed that MCOLN2 and HOXD13 may be potential therapeutic targets
.

Key recommendation 3: Sequencing and multi-omics prediction of prostate cancer efficacy The above two studies were published in the JOURANAL OF UROLOGY
.

The first study suggests that homologous recombination repair-deficient metastatic castration-resistant prostate cancer responds differently to platinum-based chemotherapy, with better response to chemotherapy in patients with BRCA mutations or ATM mutations and poorer response to chemotherapy in patients with CDK12 mutations
.

The second study revealed the gene mutation characteristics of visceral metastatic prostate cancer, and found that PTEN mutations were common in visceral metastatic prostate cancer, and DDR mutations were common in liver metastatic prostate cancer
.

This study from Renji Hospital assessed differences in gene expression profiles in hormone-sensitive and castration-resistant prostate cancer
.

Key Recommendation 4: Chinese Prostate Cancer Gene Mutation Research These two studies on Chinese gene mutation explored the mutation types of patients with metastatic castration-resistant prostate cancer and the mutation types of Chinese prostate cancer patients, respectively
.

It is worth mentioning that the first study found a higher incidence of CDK12 mutations in Chinese patients
.

The second study found that patients with ATM and BRCA2 mutations had a poorer response to abiraterone, while patients with ATM and BRCA2 mutations had similar response to chemotherapy compared with mutant wild-type
.

Conclusion - The total number of articles on the research status of prostate cancer in China is on the rise, but high-quality research still needs to be further increased
.

Domestic and foreign cooperation and cooperation between different departments have increased significantly compared with last year, and it is expected that more diversified cooperation will produce better results
.

The lack of new drug research suggests that China's prostate cancer drug development is still lagging behind
.

There are few RCT studies, suggesting that more prospective clinical studies need to be carried out in China
.